Skip to main content
Web of Medicine
Radiation Oncology›Condition·Updated Jul 24, 2026·v1

Non-Small Cell Lung Cancer Radiation Management

Radiation management of NSCLC involves definitive chemoradiation for stage III disease, dose escalation for selected patients with large tumors, and palliative RT for symptom control. The ARTFORCE trial provides contemporary PRO data showing that dose escalation preserves global QoL but causes transient dyspnea and physical decline. Modern techniques (IMRT/VMAT) and strict OAR constraints are essential to minimize toxicity. Patient selection, chemotherapy integration, and proactive supportive care are critical for optimizing outcomes.

Moderate Evidence1 references·1,566 words·7 min read·v1
NSCLCradiation therapynon-small cell lung cancerchemoradiationdose escalationpatient-reported outcomesARTFORCEthoracic radiotherapyoncology
On this page

Quick Reference

RxDrug of choiceCisplatin 50 mg/m² on days 1, 8, 29, 36 + etoposide 50 mg/m² on days 1-5, 29-33 (concurrent chemoradiation for stage III NSCLC).
AltAlternativesCarboplatin AUC 5 day 1 + paclitaxel 50 mg/m² weekly during RT, or sequential chemotherapy with platinum-doublet followed by RT.
⊘AvoidECOG ≥2 (for concurrent chemoradiation), severe COPD (FEV1 <40% predicted), prior thoracic RT exceeding OAR constraints, active infection, or poor performance status precluding treatment.
DxTest of choicePET/CT with contrast for staging and target delineation; pulmonary function tests (FEV1, DLCO) for baseline lung reserve; 4D CT simulation for respiratory motion assessment.
ScKey scoreECOG performance status (0-1 for concurrent chemo-RT); V20 (%) and mean lung dose (predicts pneumonitis risk); EORTC QLQ-C30 for patient-reported outcomes.
→When to referRefer to radiation oncology for all patients with NSCLC who may benefit from RT (definitive, adjuvant, palliative). Refer to medical oncology for systemic therapy, and to palliative care for symptom management.
For stage III NSCLC, definitive concurrent chemoradiation (60-66 Gy/30-33 fx + cisplatin/etoposide) is the standard. Dose escalation (24 × 3.0-5.4 Gy) may be considered for primary tumors ≥4 cm, with careful monitoring of dyspnea and physical function. Patient-reported outcomes should guide supportive care.
This summary covers radiation management for non-small cell lung cancer (NSCLC) across stages, with emphasis on the ARTFORCE PET-Boost trial providing patient-reported outcomes for dose-escalated radiotherapy in locally advanced disease. Key topics include indications, EBRT techniques, brachytherapy, concurrent chemoradiation, adjuvant/palliative RT, toxicity, and outcomes.

Overview and Recommendations

Background

  • •Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancers, and radiation therapy plays a central role across all stages, from definitive stereotactic ablative radiotherapy (SABR) for early-stage disease to concurrent chemoradiation for unresectable stage III and palliative RT for symptom control in advanced disease. The 5-year survival for stage III NSCLC remains under 30%, driving the need to optimize both tumor control and patient quality of life.
  • •Definitive chemoradiation, combining platinum-based chemotherapy with thoracic radiotherapy, is the standard of care for unresectable stage II-III NSCLC, following landmark trials that demonstrated a survival benefit over RT alone. The concurrent approach offers a radiosensitizing effect and addresses micrometastases, but at the cost of increased acute esophagitis and pneumonitis.
  • •Dose escalation beyond 60-66 Gy has been explored to improve local control, with the ARTFORCE PET-Boost trial evaluating an individualized regimen of 24 × 3.0-5.4 Gy to the primary tumor in patients with a tumor ≥4 cm. This strategy delivers a biologically equivalent dose >80 Gy while respecting organ-at-risk constraints, and the trial showed that average health-related quality of life (HRQoL) remained stable over 12 months, despite some transient symptom burdens.
  • •The paradigm of radiation management for NSCLC increasingly emphasizes patient-reported outcomes (PROs) alongside traditional endpoints. The ARTFORCE trial set a new standard by reporting PROs using EORTC QLQ-C30 and QLQ-LC13, revealing that clinically meaningful worsening of dyspnoea occurs at 3-6 months and physical functioning declines gradually, even when global HRQoL is preserved. This dissociation between symptoms and global QoL has important implications for counseling and proactive management.
  • •Radiation techniques have evolved from conventional 2D planning to modern intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), allowing steep dose gradients and sparing of organs at risk such as the lung (mean lung dose <20 Gy, V20 <35%), heart (mean <26 Gy), spinal cord (max <50 Gy), and esophagus. These advances make dose escalation feasible without prohibitive toxicity, though careful patient selection remains critical.

Evaluation

  • •Suspect the need for definitive radiation therapy in any patient with stage II-III NSCLC who is not a surgical candidate due to medical comorbidities, tumor extent, or patient preference. Also consider RT in the adjuvant setting for positive margins or nodal involvement after surgery, and for palliation of symptoms such as hemoptysis, pain, or airway obstruction.
  • •Ask about the patient's performance status (ECOG 0-1 generally required for concurrent chemoradiation), smoking history, pulmonary function (baseline dyspnea, COPD), and any prior thoracic radiation that would limit dose.
  • •Examine the patient for signs of superior vena cava syndrome, stridor, or distant metastases. Assess weight loss and nutritional status, as cachexia may affect tolerance to treatment.
  • •Order a staging PET/CT to define the extent of disease and identify the most FDG-avid subvolume of the primary tumor, which may be used for dose-escalation planning. Obtain a diagnostic contrast-enhanced CT of the chest and upper abdomen, and brain MRI to rule out intracranial metastases.
  • •Perform pulmonary function tests (PFTs) including FEV1 and DLCO to assess baseline lung reserve; a low FEV1 (<40% predicted) or DLCO may increase the risk of radiation pneumonitis and influence the decision for concurrent chemotherapy.
  • •Assess eligibility for dose escalation: the ARTFORCE trial offered dose-escalated RT (24 × 3.0-5.4 Gy) to patients with a primary tumor ≥4 cm. Consider this strategy in patients with adequate lung function and tumor geometry that allows meeting OAR constraints.
  • •Discuss the benefit-toxicity trade-off with the patient: explain that dose escalation may improve local control but is associated with transient worsening of dyspnea at 3-6 months and a gradual decline in physical function that can persist at 18 months. Emphasize that average global HRQoL is likely to remain stable.
  • •Plan simulation with the patient in a reproducible position (supine, arms up), using a 4D CT scan to account for respiratory motion. Consider gating or breath-hold techniques if tumor motion exceeds 1 cm.
  • •Define target volumes: GTV includes the primary tumor and involved nodes; CTV adds a 0.5-1 cm margin; PTV adds an additional margin for setup uncertainty. For dose escalation, the high-dose volume may be the whole tumor or the FDG-avid subvolume.
  • •Apply OAR constraints: spinal cord max <50 Gy, lung mean <20 Gy and V20 <35%, heart mean <26 Gy and V30 <46%, esophagus mean <34 Gy and V35 <50%. These constraints are critical to minimize late toxicity.
  • •Monitor for acute toxicity during treatment: weekly assessment of dysphagia, fatigue, and weight loss. Consider prophylactic nutritional support (e.g., enteral feeding if weight loss >5%) and use of oral mucositis protocols.
  • •After treatment, follow up with clinical evaluation and imaging at 3, 6, 12, and 18 months. Assess for late dyspnea (suggestive of radiation pneumonitis) and declining physical function. Use PRO questionnaires (e.g., EORTC QLQ-C30) to capture symptom burden systematically.

Management

  • •For stage III unresectable NSCLC with good performance status (ECOG 0-1), initiate definitive concurrent chemoradiation: deliver 60-66 Gy in 30-33 fractions (1.8-2.0 Gy/fraction) with cisplatin 50 mg/m² on days 1, 8, 29, 36 and etoposide 50 mg/m² on days 1-5, 29-33. Alternatively, use carboplatin AUC 5 day 1 + paclitaxel 50 mg/m² weekly during RT.
  • •For patients with a primary tumor ≥4 cm who are candidates for dose escalation, consider the ARTFORCE regimen: 24 fractions of 3.0-5.4 Gy (individualized to OAR constraints) to the whole tumor or the FDG-avid subvolume. This can be delivered with concurrent or sequential chemotherapy, or RT alone. Monitor PROs closely.
  • •For patients with ECOG 2 or contraindications to concurrent chemotherapy, administer sequential chemoradiation: 2-4 cycles of platinum-doublet chemotherapy followed by RT (60-66 Gy/30-33 fx). Alternatively, RT alone can be used for frail patients.
  • •For early-stage (stage I) NSCLC, use stereotactic ablative radiotherapy (SABR): 48-60 Gy in 3-5 fractions (e.g., 54 Gy/3 fx for peripheral tumors, 50 Gy/5 fx for central tumors). This is not discussed in the provided evidence but is a standard first-line RT option for medically inoperable patients.
  • •For postoperative adjuvant RT, consider RT (50-60 Gy in 25-30 fx) for patients with positive margins or N2 nodal involvement. The decision should be multidisciplinary, balancing the risk of local recurrence against increased toxicity.
  • •For palliation of symptoms (e.g., hemoptysis, pain, dyspnea from airway obstruction), deliver hypofractionated RT: 30 Gy in 10 fractions, 20 Gy in 5 fractions, or 8-10 Gy single fraction for bone metastases. Use IMRT/VMAT to spare surrounding normal tissues.
  • •Integrate chemotherapy with RT: for concurrent chemoradiation, use cisplatin-based regimens as first-line. For patients with impaired renal function or hearing loss, substitute carboplatin. Avoid concurrent use of targeted therapies or immune checkpoint inhibitors with RT unless part of a clinical trial.
  • •Titrate supportive care: start prophylactic dexamethasone 0.5 mg/kg/day IV (or equivalent) for esophagitis pain, and consider proton pump inhibitors. Use enteral feeding if oral intake is inadequate. Manage radiation pneumonitis with prednisone 1 mg/kg/day tapered over 4-6 weeks.
  • •Monitor for acute toxicity during treatment: weekly CBC, weight, and toxicity assessment. For grade ≥3 esophagitis (NCI CTCAE), hold chemotherapy and consider RT breaks. For grade ≥3 pneumonitis, start corticosteroids and hold RT.
  • •After treatment, schedule follow-up visits at 3, 6, 12, and 18 months, then annually. Perform CT chest at each visit. Assess for late effects: radiation fibrosis, pericarditis, myelopathy. Use PRO tools to capture dyspnea and physical functioning.
  • •What NOT to do: do not escalate dose without respecting OAR constraints; do not use concurrent chemo in patients with ECOG ≥2 or severe PFT impairment; do not ignore PROs, proactively address dyspnea and fatigue with pulmonary rehabilitation and exercise programs.
  • •Refer to a radiation oncologist for all patients with NSCLC who may benefit from RT. Refer to a medical oncologist for systemic therapy integration. Refer to a palliative care specialist for symptom management and advanced care planning, especially in the metastatic setting.
  • •Discharge criteria: after completing RT, patients can be discharged from the radiation oncology clinic when acute toxicity is resolved (typically 2-4 weeks after last fraction) and follow-up imaging is scheduled. Provide survivorship care plan including monitoring for late effects.

Board Review — High Yield

  • •Concurrent chemoradiation, Standard of care for stage III unresectable NSCLC; improves OS over RT alone. Use cisplatin/etoposide or carboplatin/paclitaxel.
  • •Standard dose, 60-66 Gy in 30-33 fractions (1.8-2.0 Gy/fx). Deliver with IMRT/VMAT to spare OARs.
  • •Dose escalation, ARTFORCE trial: 24 × 3.0-5.4 Gy for primary tumor ≥4 cm; preserves average HRQoL but causes transient dyspnea at 3-6 months.
  • •OAR constraints, Lung: V20 <35%, mean <20 Gy; Heart: mean <26 Gy, V30 <46%; Spinal cord: max <50 Gy; Esophagus: mean <34 Gy, V35 <50%.
  • •Patient-reported outcomes, EORTC QLQ-C30 and LC13; compliance drops during RT (35%) but recovers. Global QoL stable despite symptom burden.
  • •Palliative RT, Hypofractionated regimens: 30 Gy/10 fx, 20 Gy/5 fx, or 8-10 Gy single for bone metastases. Effective for hemoptysis, pain, obstruction.
  • •Adjuvant RT, Consider for positive margins or N2 disease post-surgery; dose 50-60 Gy in 25-30 fx. Balance benefit with increased cardiac/pulmonary toxicity.
  • •Toxicity monitoring, Acute: esophagitis, fatigue, weight loss. Late: pneumonitis (dyspnea at 3-6 months), radiation fibrosis, pericarditis. Proactive symptom management is key.

Deep Dive — Evidence Details

References

  1. [1]

    Cooke SA, Belderbos JSA, Reymen B et al.. “Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024). PMID: 38663582 ↗

    L2RCT_PHASE2Cited in: Indications by Stage, External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation, Adjuvant and Palliative RT, Acute and Late Toxicity, Outcomes

Backlinks

Revision History

All updates applied to this page

Loading revisions…